Our approach

Change the route, not the medicine.

Many promising medicines are given by needle because the digestive system destroys them or absorbs them poorly. We design dosage forms that take a different route into the body.

A thin, translucent film curling on a pale surface

Platform one

A film that works through the cheek.

The lining of the cheek has a rich blood supply and none of the stomach’s digestive enzymes. Our buccal thin film is engineered for peptides from the start, to hold a measured dose against that tissue.

  1. The film is pressed against the inside of the cheek, where it stays in place.
  2. The peptide moves from the film across the cheek lining.
  3. It reaches the bloodstream without passing through the stomach or the liver first.

Design goal: exposure comparable to the injected form of the same medicine.

Translucent golden softgel capsules

Platform two

A softgel that protects its contents.

Some established medicines can be swallowed but are absorbed poorly, or differently from one day to the next. Our enteric softgel is designed to carry them past the stomach and release where absorption is better.

  1. The softgel is swallowed like any other.
  2. Its shell is designed to pass through the stomach intact and open in the intestine.
  3. The contents are formulated to favor lymphatic uptake, which bypasses part of first-pass liver metabolism.

Design goal: steadier, more predictable exposure from an oral dose.

Development path

Progress measured in proof.

Each program moves through the same sequence, and we publish performance figures only once they have been measured.

  1. 01

    Formulation and feasibility

    Design of the dosage form and manufacturing feasibility with specialist partners.

    Current stage
  2. 02

    Laboratory validation

    Independent laboratory testing against criteria fixed in advance.

  3. 03

    Human pharmacokinetics

    Small clinical studies that measure exposure against the reference medicine.

  4. 04

    Regulatory pathway

    Review by the relevant authority in each market before any product is supplied.

Disclosure

What we share, and when.

This site is a general overview.

The BioUnbound platforms are patent pending. Formulation, manufacturing and intellectual property details are confidential and are shared with qualified partners under a confidentiality agreement.

Contact the team to start that conversation.

Contact

Let’s explore what comes next.

For company information, partnership discussions, or investor and media enquiries, connect with the BioUnbound team.